Subscribe To
Relay therapeutics highlights interim data from bile duct cancer trial
Relay Therapeutics Inc (NASDAQ: RLAY) has announced an interim data Phase 1 trial of RLY-4008 in FGFR2-altered cholangiocarcinoma (bile duct cancer...
October 8, 2021, 12:24 pm
Ctx-009 (abl001/es104) clinical data presented today at the new drugs on the horizon plenary session of the 2021 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
BOSTON & SEONGNAM, S. Korea & SHANGHAI/SUZHOU, China--(BUSINESS WIRE)-- #AACR--CTX-009 (ABL001/ES104) clinical data presented today at the New Drugs o...
October 8, 2021, 12:07 pm
Ctx-009 (abl001/es104) clinical data presented today at the new drugs on the horizon plenary session of the 2021 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
BOSTON & SEONGNAM, S. Korea & SHANGHAI/SUZHOU, China--(BUSINESS WIRE)-- #AACR--CTX-009 (ABL001/ES104) clinical data presented today at the New Drugs o...
October 8, 2021, 12:07 pm
Ctx-009 (abl001/es104) clinical data presented today at the new drugs on the horizon plenary session of the 2021 aacr-nci-eortc international conference on molecular targets and cancer therapeutics
BOSTON & SEONGNAM, S. Korea & SHANGHAI/SUZHOU, China--(BUSINESS WIRE)-- #AACR--CTX-009 (ABL001/ES104) clinical data presented today at the New Drugs o...
October 8, 2021, 12:07 pm
Effector therapeutics stock gains on encouraging preclinical zotatifin data in breast cancer
eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zo...
October 8, 2021, 7:34 am
Effector therapeutics stock gains on encouraging preclinical zotatifin data in breast cancer
eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zo...
October 8, 2021, 7:34 am
Effector therapeutics stock gains on encouraging preclinical zotatifin data in breast cancer
eFFECTOR Therapeutics Inc (NASDAQ: EFTR), in collaboration with Baylor College of Medicine, announced the presentation of new positive data for zo...
October 8, 2021, 7:34 am
Evotec expands neuroscience collaboration with bristol myers squibb to include novel cell type
INCLUDES NEW CELL TYPES FOR STUDYING moleCULAR DISEASE SIGNATURES FOR DISCOVERY OF DISEASE-MODIFYING TH...
October 8, 2021, 1:50 am
Evotec expands neuroscience collaboration with bristol myers squibb to include novel cell type
INCLUDES NEW CELL TYPES FOR STUDYING moleCULAR DISEASE SIGNATURES FOR DISCOVERY OF DISEASE-MODIFYING TH...
October 8, 2021, 1:50 am
Evotec expands neuroscience collaboration with bristol myers squibb to include novel cell type
INCLUDES NEW CELL TYPES FOR STUDYING moleCULAR DISEASE SIGNATURES FOR DISCOVERY OF DISEASE-MODIFYING TH...
October 8, 2021, 1:50 am
Repare therapeutics issues statement regarding inadvertent issuance of phase 1/2 tresr rp-3500 clinical trial abstract by the aacr-nci-eortc virtual international conference
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 7, 2021, 5:08 pm
Repare therapeutics issues statement regarding inadvertent issuance of phase 1/2 tresr rp-3500 clinical trial abstract by the aacr-nci-eortc virtual international conference
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 7, 2021, 5:08 pm
Repare therapeutics issues statement regarding inadvertent issuance of phase 1/2 tresr rp-3500 clinical trial abstract by the aacr-nci-eortc virtual international conference
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage pr...
October 7, 2021, 5:08 pm
Lava therapeutics to present its bispecific gamma delta t cell engagers for treatment of cancer at the 2021 aacr-nci-eortc virtual international conference on molecular targets and cancer therapeutics
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology com...
October 7, 2021, 11:31 am
Lava therapeutics to present its bispecific gamma delta t cell engagers for treatment of cancer at the 2021 aacr-nci-eortc virtual international conference on molecular targets and cancer therapeutics
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology com...
October 7, 2021, 11:31 am
Lava therapeutics to present its bispecific gamma delta t cell engagers for treatment of cancer at the 2021 aacr-nci-eortc virtual international conference on molecular targets and cancer therapeutics
UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology com...
October 7, 2021, 11:31 am
Immunotherapeutic benefits of the dpx delivery platform featured in two poster presentations at the aacr-nci-eortc conference on molecular targets and cancer therapeutics
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceu...
October 7, 2021, 9:05 am
Immunotherapeutic benefits of the dpx delivery platform featured in two poster presentations at the aacr-nci-eortc conference on molecular targets and cancer therapeutics
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceu...
October 7, 2021, 9:05 am
Immunotherapeutic benefits of the dpx delivery platform featured in two poster presentations at the aacr-nci-eortc conference on molecular targets and cancer therapeutics
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceu...
October 7, 2021, 9:05 am
Recursion is granted fda fast track designation for rec-2282 for the potential treatment of nf2-mutated meningiomas
SALT LAKE CITY, Oct. 7, 2021 /PRNewswire/ -- Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technol...
October 7, 2021, 7:55 am